In March 2022,[177Lu] Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the
treatment of prostate cancer patients. Until now, the approval has been limited to patients …

Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …

Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …

Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …

Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …

Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

Summary Background Lutetium-177 [177 Lu] Lu-PSMA-617 is a radiolabelled small
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …

177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …